Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks
Vipul Jain, Ana M. Giménez‐Arnau, Koremasa Hayama, Adam Reich, Warner Carr, Jeffrey Tillinghast, Swapnil Dahale, K. Lheritier, Pauline Walsh, Artem Zharkov, Sophie Hugot, Sibylle Haemmerle
Topics & Concepts
MedicineSafety profileChronic urticariaDermatologyInternal medicineAdverse effectUrticaria and Related ConditionsCoagulation, Bradykinin, Polyphosphates, and AngioedemaAutoimmune Bullous Skin Diseases